Beam Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
17.00
0.38
(2.29%)
Volume:
1,136,640
52 week range:
13.53 - 35.25
Market Cap:
1.423B
Company Description:
Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.